Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers

Human Molecular Genetics

Volumn 18, Issue 22, 2009, Pages 4442-4456

  Antoniou, Antonis C ^a   Sinilnikova, Olga M ^b   McGuffog, Lesley ^a   Healey, Sue ^c   Nevanlinna, Heli ^d   Heikkinen, Tuomas ^d   Simard, Jacques ^e   Spurdle, Amanda B ^c   Beesley, Jonathan ^c   Chen, Xiaoqing ^c   Neuhausen, Susan L ^f   Ding, Yuan C ^f   Couch, Fergus J ^g   Wang, Xianshu ^g   Fredericksen, Zachary ^g   Peterlongo, Paolo ^h,i   Peissel, Bernard ^h   Bonanni, Bernardo ^j   Viel, Alessandra ^k   Bernard, Loris ^j,l   Radice, Paolo ^h,i   Szabo, Csilla I ^m   Foretova, Lenka ⁿ   Zikan, Michal ^o   Claes, Kathleen ^p   Greene, Mark H ^q   Mai, Phuong L ^q   Rennert, Gad ^r   Lejbkowicz, Flavio ^r   Andrulis, Irene L ^s,t,u   Ozcelik, Hilmi ^t   Glendon, Gord ^s   Gerdes, Anne Marie ^v   Thomassen, Mads ^v   Sunde, Lone ^w   Caligo, Maria A ^x   Laitman, Yael ^y   Kontorovich, Tair ^y   Cohen, Shimrit ^y   Kaufman, Bella ^z,aa   Dagan, Efrat ^ab   Baruch, Ruth Gershoni ^ab   Friedman, Eitan ^y,aa   Harbst, Katja ^ac   Barbany Bustinza, Gisela ^ad   Rantala, Johanna ^ad   Ehrencrona, Hans ^ae   Karlsson, Per ^af   Domchek, Susan M ^ag   Nathanson, Katherine L ^ag   Osorio, Ana ^ah   Blanco, Ignacio ^ai   Lasa, Adriana ^aj   Benítez, Javier ^ah   Hamann, Ute ^ak   Hogervorst, Frans B L ^al   Rookus, Matti A ^al   Collee, J Margriet ^am   Devilee, Peter ^an   Ligtenberg, Marjolijn J ^ao   van der Luijt, Rob B ^ap   Aalfs, Cora M ^aq   Waisfisz, Quinten ^ar   Wijnen, Juul ^an   van Roozendaal, Cornelis E P ^as   Peock, Susan ^a   Cook, Margaret ^a   Frost, Debra ^a   Oliver, Clare ^a   Platte, Radka ^a   Evans, D Gareth ^at   Lalloo, Fiona ^at   Eeles, Rosalind ^au   Izatt, Louise ^av   Davidson, Rosemarie ^aw   Chu, Carol ^ax   Eccles, Diana ^ay   Cole, Trevor ^az   Hodgson, Shirley ^ba   Godwin, Andrew K ^bb   Stoppa Lyonnet, Dominique ^bc   Buecher, Bruno ^bd   Léoné, Méanie ^b   Bressac de Paillerets, Brigitte ^be   Remenieras, Audrey ^be   Caron, Olivier ^be   Lenoir, Gilbert M ^be   Sevenet, Nicolas ^bf   Longy, Michel ^bf   Ferrer, Sandra Fert ^bg   Prieur, Fabienne ^bh   Goldgar, David ^bi   Miron, Alexander ^bj   John, Esther M ^bk,bl   Buys, Saundra S ^bm   Daly, Mary B ^bb   Hopper, John L ^bn   Terry, Mary Beth ^bo   Yassin, Yosuf ^bj   Singer, Christian ^bp   Gschwantler Kaulich, Daphne ^bp   Staudigl, Christine ^bp   Hansen, Thomas V O ^bq   Barkardottir, Rosa Bjork ^br   Kirchhoff, Tomas ^bs   Pal, Prodipto ^bs   Kosarin, Kristi ^bs   Offit, Kenneth ^bs   Piedmonte, Marion ^bt   Rodriguez, Gustavo C ^bu   Wakeley, Katie ^bv   Boggess, John F ^bw   Basil, Jack ^bx   Schwartz, Peter E ^by   Blank, Stephanie V ^bz   Toland, Amanda E ^ca,cb   Montagna, Marco ^cc   Casella, Cinzia ^cc   Imyanitov, Evgeny N ^cd   Allavena, Anna ^ce   Schmutzler, Rita K ^cf   Versmold, Beatrix ^cf   Engel, Christoph ^cg   Meindl, Alfons ^ch   Ditsch, Nina ^ci   Arnold, Norbert ^cj   Niederacher, Dieter ^cj   Deißler, Helmut ^ck   Fiebig, Britta ^cl   Suttner, Christian ^cm   Schönbuchner, Ines ^cn   Gadzicki, Dorothea ^co   Caldes, Trinidad ^cp   de la Hoya, Miguel ^cp   Pooley, Karen A ^a   Easton, Douglas F ^a   Chenevix Trench, Georgia ^c   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITÉ DE LYON   (France)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITÉ LAVAL   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g MAYO CLINIC   (United States)

^h NATIONAL CANCER INSTITUTE   (Italy)

ⁱ FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^l Consortium for Genomic Technologies ^*  (Italy)

^m Mayo Clinic   (United States)

ⁿ MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^o CHARLES UNIVERSITY   (Czech Republic)

^p GHENT UNIVERSITY HOSPITAL   (Belgium)

^q NATIONAL CANCER INSTITUTE   (United States)

^r TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^s CANCER CARE ONTARIO   (Canada)

^t MOUNT SINAI HOSPITAL   (Canada)

^u UNIVERSITY OF TORONTO   (Canada)

^v ODENSE UNIVERSITY HOSPITAL   (Denmark)

^w AARHUS UNIVERSITY HOSPITAL   (Denmark)

^x UNIVERSITY OF PISA   (Italy)

^y SHEBA MEDICAL CENTER   (Israel)

^z The Oncology Institute Chaim Sheba Medical Center   (Israel)

^aa TEL AVIV UNIVERSITY   (Israel)

^ab RAMBAM MEDICAL CENTER   (Israel)

^ac LUND UNIVERSITY   (Sweden)

^ad KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^ae UPPSALA UNIVERSITY   (Sweden)

^af Sahlgrenska University   (Sweden)

^ag UNIVERSITY OF PENNSYLVANIA   (United States)

^ah Centro Nacional de Investigaciones Oncológicas   (Spain)

^ai CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^aj HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^ak GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^al NETHERLANDS CANCER INSTITUTE   (Netherlands)

^am ERASMUS MEDICAL CENTER   (Netherlands)

^an LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^ao RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^ap UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^aq ACADEMIC MEDICAL CENTER   (Netherlands)

^ar VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^as MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^at UNIVERSITY OF MANCHESTER   (United Kingdom)

^au INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^av GUY S HOSPITAL   (United Kingdom)

^aw Ferguson Smith Centre for Clinical Genetics   (United Kingdom)

^ax Yorkshire Regional Genetics Service   (United Kingdom)

^ay PRINCESS ANNE HOSPITAL   (United Kingdom)

^az BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^ba ST GEORGE S HOSPITAL   (United Kingdom)

^bb FOX CHASE CANCER CENTER   (United States)

^bc INSERM   (France)

^bd INSTITUT CURIE   (France)

^be INSTITUT GUSTAVE ROUSSY   (France)

^bf INSTITUT BERGONIÉ   (France)

^bg CENTRE HOSPITALIER DE CHAMBÉRY   (France)

^bh UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^bi UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^bj DANA FARBER CANCER INSTITUTE   (United States)

^bk NORTHERN CALIFORNIA CANCER CENTER   (United States)

^bl STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^bm UNIVERSITY OF UTAH   (United States)

^bn UNIVERSITY OF MELBOURNE   (Australia)

^bo Och Spine at New York Presbyterian Hospitals   (United States)

^bp MEDICAL UNIVERSITY OF VIENNA   (Austria)

^bq Rigshospitalet   (Denmark)

^br LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^bs MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^bt ROSWELL PARK CANCER INSTITUTE   (United States)

^bu NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^bv TUFTS UNIVERSITY   (United States)

^bw UNIVERSITY OF NORTH CAROLINA   (United States)

^bx St Elizabeth Medical Center   (United States)

^by YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^bz NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ca THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^cb OHIO STATE UNIVERSITY   (United States)

^cc VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^cd N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^ce UNIVERSITY OF TURIN   (Italy)

^cf UNIVERSITY OF COLOGNE   (Germany)

^cg UNIVERSITY OF LEIPZIG   (Germany)

^ch TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^ci UNIVERSITY OF MUNICH   (Germany)

^cj HEINRICH HEINE UNIVERSITY   (Germany)

^ck UNIVERSITY OF ULM   (Germany)

^cl UNIVERSITY OF REGENSBURG   (Germany)

^cm UNIVERSITY OF HEIDELBERG   (Germany)

^cn UNIVERSITY OF WÜRZBURG   (Germany)

^co HANNOVER MEDICAL SCHOOL   (Germany)

^cp HOSPITAL CLÍNICO SAN CARLOS   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ONCOPROTEIN; PROTEIN LSP1; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 71049194443     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddp372     Document Type: Article

References (26)

1. Antoniou, A., Pharoah, P.D., Narod, S., Risch, H.A., Eyfjord, J.E., Hopper, J.L., Loman, N., Olsson, H., Johannsson, O., Borg, A. et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet., 72, 1117-1130.
2. Antoniou, A.C., Cunningham, A.P., Peto, J., Evans, D.G., Lalloo, F., Narod, S.A., Risch, H.A., Eyfjord, J.E., Hopper, J.L., Southey, M.C. et al. (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: Updates and extensions. Br. J. Cancer, 98 1457-1466.
3. Begg, C.B., Haile, R.W., Borg, A., Malone, K.E., Concannon, P., Thomas, D.C., Langholz, B., Bernstein, L., Olsen, J.H., Lynch, C.F. et al. (2008) Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299, 194-201.
4. Hopper, J.L., Southey, M.C., Dite, G.S., Jolley, D.J., Giles, G.G., McCredie, M.R., Easton, D.F. and Venter, D.J. (1999) Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol. Biomarkers Prev., 8, 741-747.
5. Milne, R.L., Osorio, A., Cajal, T.R., Vega, A., Llort, G., de la Hoya, M., Diez, O., Alonso, M.C., Lazaro, C., Blanco, I. et al. (2008) The Average Cumulative Risks of Breast and Ovarian Cancer for Carriers of Mutations in BRCA1 and BRCA2 Attending Genetic Counseling Units in Spain. Clin. Cancer Res., 14, 2861-2869.
6. Simchoni, S., Friedman, E., Kaufman, B., Gershoni-Baruch, R., Orr-Urtreger, A., Kedar-Barnes, I., Shiri-Sverdlov, R., Dagan, E., Tsabari, S., Shohat, M. et al. (2006) Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc. Natl Acad. Sci. USA, 103 3770-3774.
7. Struewing, J.P., Hartge, P., Wacholder, S., Baker, S.M., Berlin, M., McAdams, M., Timmerman, M.M., Brody, L.C. and Tucker, M.A. (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med., 336, 1401-1408.
8. Antoniou, A.C., Spurdle, A.B., Sinilnikova, O.M., Healey, S., Pooley, K.A., Schmutzler, R.K., Versmold, B., Engel, C., Meindl, A., Arnold, N. et al. (2008) Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am. J. Hum. Genet., 82, 937-948.
9. Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D., Thompson, D., Ballinger, D.G., Struewing, J.P., Morrison, J., Field, H., Luben, R. et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 447, 1087-1093.
10. Hunter, D.J., Kraft, P., Jacobs, K.B., Cox, D.G., Yeager, M., Hankinson, S.E., Wacholder, S., Wang, Z., Welch, R., Hutchinson, A. et al. (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet., 39, 870-874.
11. Stacey, S.N., Manolescu, A., Sulem, P., Rafnar, T., Gudmundsson, J., Gudjonsson, S.A., Masson, G., Jakobsdottir, M., Thorlacius, S., Helgason, A. et al. (2007) Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet., 39, 865-869.
12. Milne, R.L., Benítez, J.B., Nevanlinna, H., Heikkinen, T., Aittomäki, K., Blomqvist, C., Arias, J.I., Zamora, M.P., Burwinkel, B., Bartram, C.R. et al. (2009) Risk of estrogen receptor-positive and -negative breast cancer and SNP rs13387042 on 2q35. J. Natl. Cancer Inst., 101, 1012-1018.
13. Lakhani, S.R., Reis-Filho, J.S., Fulford, L., Penault-Llorca, F., van der Vijver, M., Parry, S., Bishop, T., Benitez, J., Rivas, C., Bignon, Y.J. et al. (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin. Cancer Res., 11, 5175-5180.
14. Garcia-Closas, M., Hall, P., Nevanlinna, H., Pooley, K., Morrison, J., Richesson, D.A., Bojesen, S.E., Nordestgaard, B.G., Axelsson, C.K., Arias, J.I. et al. (2008) Heterogeneity of breast cancer associations with five susceptibility Loci by clinical and pathological characteristics. PLoS Genet., 4, e1000054.
15. Antoniou, A.C., Sinilnikova, O.M., Simard, J., Leone, M., Dumont, M., Neuhausen, S.L., Struewing, J.P., Stoppa-Lyonnet, D., Barjhoux, L., Hughes, D.J. et al. (2007) RAD51 135G->C modifies breast cancer risk among BRCA2 mutation carriers: Results from a combined analysis of 19 studies. Am. J. Hum. Genet., 81, 1186-1200.
16. Chenevix-Trench, G., Milne, R.L., Antoniou, A.C., Couch, F.J., Easton, D.F. and Goldgar, D.E. (2007) An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res., 9, 104.
17. Antoniou, A.C., Goldgar, D.E., Andrieu, N., Chang-Claude, J., Brohet, R., Rookus, M.A. and Easton, D.F. (2005) A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. Genet. Epidemiol., 29, 1-11.
18. Lange, K., Weeks, D. and Boehnke, M. (1988) Programs for pedigree analysis: MENDEL, FISHER, and dGENE. Genet. Epidemiol., 5, 471-472.
19. Huber, P.J. (1967) The behavior of maximum likelihood estimates under non-standard conditions. Proceedings of the Fifth Berkley Symposium in Mathematical Statistics and Probability. Vol. 1, pp. 221-233.
20. Mikaelsdottir, E.K., Valgeirsdottir, S., Eyfjord, J.E. and Rafnar, T. (2004) The Icelandic founder mutation BRCA2 999del5: Analysis of expression. Breast Cancer Res., 6, R284-R290.
21. Montagna, M., Agata, S., De, N.A., Menin, C., Sordi, G., Chieco-Bianchi, L. and D'Andrea, E. (2002) Identification of BRCA1 and BRCA2 carriers by allele-specific gene expression (AGE) analysis. Int. J. Cancer, 98, 732-736.
22. Perrin-Vidoz, L., Sinilnikova, O.M., Stoppa-Lyonnet, D., Lenoir, G.M. and Mazoyer, S. (2002) The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum. Mol. Genet., 11, 2805-2814.
23. Ware, M.D., DeSilva, D., Sinilnikova, O.M., Stoppa-Lyonnet, D., Tavtigian, S.V. and Mazoyer, S. (2006) Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene? Oncogene 25, 323-328.
24. Buisson, M., Anczukow, O., Zetoune, A.B., Ware, M.D. and Mazoyer, S. (2006) The 185delAG mutation (c.68_69delAG) in the BRCA1 gene triggers translation reinitiation at a downstream AUG codon. Hum. Mutat., 27, 1024-1029.
25. Antoniou, A.C. and Easton, D.F. (2003) Polygenic inheritance of breast cancer: Implications for design of association studies. Genet. Epidemiol., 25, 190-202.
26. Risch, N. (1990) Linkage strategies for genetically complex traits. I. Multilocus models. Am. J Hum. Genet., 46, 222-228.